Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA has granted investigational device exemption to Ciliatech’s Intercil uveal spacer for glaucoma, according to a company press release.
With the approval, the company plans to begin a new feasibility study to evaluate the safety and performance of the device in approximately 30 patients with primary open-angle glaucoma, according to the release.
Intercil in a hydrophilic acrylic implant designed to support uveoscleral outflow by creating supraciliary spacing. The company said it is meant to be a